

Title: Clustering of substance use and sexual risk behaviour in adolescence: analysis of two cohort studies

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	<b>Item No</b>	<b>Recommendation</b>	<b>Reported on page No.</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title (cohort studies)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p2-3
Objectives	3	State specific objectives, including any prespecified hypotheses	p3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	p3-4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p3-4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	p3-4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p4-5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p3-4
Bias	9	Describe any efforts to address potential sources of bias	p5 (calculated attrition-based weights to account for attrition)
Study size	10	Explain how the study size was arrived at	Not reported*
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p4-5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p5-6
		(b) Describe any methods used to examine subgroups and interactions	p5-6
		(c) Explain how missing data were addressed	p5
		(d) If applicable, explain how loss to follow-up was addressed	P5
		(e) Describe any sensitivity analyses	None

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Reported in Methods (p3-4 and in Table 1 of results)
		(b) Give reasons for non-participation at each stage	Reported in methods p3-4
		(c) Consider use of a flow diagram	Not used
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Reported in table 1
		(b) Indicate number of participants with missing data for each variable of interest	Indicated in methods (p3-4) and can be deduced from table 1
		(c) Summarise follow-up time (eg, average and total amount)	Described in methods
Outcome data	15*	Report numbers of outcome events or summary measures over time	Given in tables and in first paragraph of results (p6)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Unadjusted estimates reported in tables 2 and 3 and in text (p7-8). Adjusted findings reported in figures 1 and 2 and in text (p7-8)
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Reported in p7-8
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	p8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P8-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	Considered amongst the limitations (p9)
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p12

\*Given that this is a secondary analysis of existing cohorts, we did not carry out any sample size calculations for this particular analysis. However, these calculations were done when the cohorts were set up. We did not think it was appropriate to include these in this particular report.